The effectiveness, safety and economic rationality of the neoadjuvant chemotherapy with biosimilar of Trastuzumab in HER2+ breast cancer in Russian clinical practice.

• DOI: 10.1200/jco.2018.36.15_suppl.e12656
• Publication Date: 2018-09-05T10:14:13Z
• Authors: Irina Vladimirovn...; I. Ganshina; Lyudmila Zhukova; Olga Gordeeva; Vahan Yurikovich ...; Dmitrii Komov; Olga Pavlikova; Yana V Vishnevskaya; Irina Poddubnaya
• Keywords: Biosimilar; Clinical Practice; Pertuzumab

e12656 Background: The biosimilar of trastuzumab (Herticad ®) used in Russian clinical practice since March 2016, but the effectiveness, safety and economic rationality (BT) neoadjuvant chemotherapy HER2+ breast cancer (BC) have not been previously reported. Methods: In our study included 55 women with BC stage II-III treated National Research Cancer Center 2016 to December 2017 (median age- 52; range - 28-80 years). Neoadjuvant was all (sequential combination anthracyclines taxanes, AC→T 59,3%, taxanes plus carboplatin, DC -37%, only -3,7%) BT at a standard dose 6 mg/kg (loading first 8 mg/kg), every 3 weeks. Primary-operable stages were 45,5%, locally advance 54,4%. Grade tumors G2 83%, G3- 17%; luminal seen non-luminal 54,5%. After had radical surgery an assessment pathological response. We analyzed rate complete response (pCR), BT, statistical analysis made by SPSS 20,0. Results: pCR 55,6% (breast) 45,8% (breast lymph nodes). same primary-operable locally-advance (58,6 vs 52%, p = 0,625), as well (54,2 56,7%, 0,854). But significantly depend from grade (G2- 49%, 86%, 0,01), regime (AC→T – 45,2%, -70%, р 0,033) number cycles (4 cycles- 48,5%, 65%, 100%, 0,01). Toxicity corresponded chemotherapy-regimen chosen. No treatment-associated cardiac dysfunction occurred any patients enrolled study. infusion-related reactions registered. cost therapy decreased 75% 2017. Conclusions: effective, safe economically reasonable II-III.